SimpleFunctions
Winner-take-all answer·4 source contracts·Kalshi 4·refreshed just now·Closes Jan 1, 2027 · 192d

When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List

Leader sits at 58% across 4 bound outcomes, runner-up at 52%. This is a winner-take-all market — the headline is the leader’s price, not an arithmetic mean.

Leader probability

58%

Before 2027

runner-up 52¢leader 58¢

Outcomes

4

winner-take-all

Runner-up

52¢

Before November

Spread

6pp

contested

24h volume

$604

thin orderbook

Closes

Jan 1, 2027

192 days

Venue

Kalshi

4 bound

30-day trend

0%50%100%-30d-3w-2w-1wtodayBefore 2027: 60% (23 days, 11 points)Before 2027: 60% on 2026-06-22Before November: 55% (23 days, 9 points)Before November: 55% on 2026-06-22Before September: 40% (23 days, 21 points)Before September: 40% on 2026-06-23
Before 202760¢Before November55¢Before September40¢
Top 3 candidates by current price · 23d

Bracket family

How the bracket ladder is priced.

Each row is one outcome on the venue. Sorted by 24h volume — the heaviest book is at the top.

Analysis

This prediction estimates a 43% chance that the FDA will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by a specific future date. The current probability reflects BPC-157's status as a peptide without FDA approval for therapeutic use, balanced against growing research interest and potential pathway movements. Key factors driving this level include the peptide's current regulatory classification, the pace of clinical research submissions, and FDA's historical approach to bulk drug categorization. The most significant catalyst would be an FDA announcement, formal petition for reclassification, or a major clinical program submission that signals regulatory acceptance. BPC-157's track record in research demonstrates bioactivity in animal models, but human clinical evidence remains limited, creating uncertainty about whether the FDA would elevate its classification status in the near term.

  • Current BPC-157 regulatory status as an unapproved investigational substance without existing Category 1 designation
  • Pace of clinical trial initiation or IND applications submitted to FDA that specifically reference BPC-157
  • Historical FDA timelines for bulk drug substance reclassifications and typical catalyst events that trigger such reviews
  • Competition from other peptide therapies with more advanced clinical development status
  • Public or regulatory signals indicating FDA's receptiveness to BPC-157 programs in therapeutic areas like gastroenterology or neuroprotection

What moved the line

  • Jun 18Before November21pp3455¢ · Kalshi
  • Jun 17Before 202717pp5942¢ · Kalshi
  • Jun 18Before 202717pp4259¢ · Kalshi
  • Jun 17Before September12pp2739¢ · Kalshi
  • Jun 17Before November8pp2634¢ · Kalshi

Recently closed in general

These markets stopped trading. Last odds and any captured outcome are shown above — full settlement detail lives at the venue.

More like this

Adjacent prediction questions.

How we compute these odds

SimpleFunctions aggregates live prediction-market contracts from Kalshi and Polymarket. Each slug groups contracts that resolve on the same underlying event, identified by venue event_id.

For binary slugs, the headline probability is the liquidity-weighted mid-price across all bound contracts. For multi-outcome slugs (e.g. elections with 3+ candidates), the headline is the leader’s price; we never arithmetically average disjoint outcomes — that would produce a number with no real-world meaning.

Snapshots refresh every 5 minutes during market hours; daily aggregates are computed at 04:00 UTC. The 30-day sparkline is drawn from per-ticker daily means stored in market_indicator_daily; 24h delta and movement events are derived from the same source.

Last updated on this page: just now.